Amount of qualified clients: CDEC talked about the uncertainty in the quantity of sufferers with moderately extreme to extreme hemophilia B in Canada eligible for etranacogene dezaparvovec. Scientific industry experts consulted by CADTH indicated that some people that are labeled as getting mild or average ailment could have a extreme https://hemgenix05936.getblogs.net/68345314/the-basic-principles-of-hemgenix